Erasca, Inc.
ERAS
Pozycja w akcjach
#3568
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Cena akcji
$13.68
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$4.78B
Zmiana (1 dzień)
2.13%
Zmiana (1 rok)
455.89%
Kraj
US
Handel Erasca, Inc. (ERAS)
Kategoria
Healthcare
Wskaźnik P/S dla Erasca, Inc. (ERAS)
Wskaźnik P/S na dzień October 2026 TTM: 0.00
Według najnowszych raportów finansowych i ceny akcji Erasca, Inc., obecny wskaźnik P/S (TTM) wynosi 0.00. Na koniec 2023 wynosił 0.00.
Historia wskaźnika P/S dla Erasca, Inc. od 2019 do 2026
Wskaźnik P/S na koniec każdego roku
| Rok | Wskaźnik P/S | Zmień |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
Wskaźnik P/S dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/S | Różnica wskaźnika P/S | Kraj |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
